{"doi":"10.3390/ijms26125883","title":"Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study","abstract":"<jats:p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of liver cirrhosis, with its global prevalence rising due to obesity, insulin resistance, and type 2 diabetes mellitus. While bariatric surgery remains effective for weight loss, Glucagon-Like Peptide-1 analogs such as liraglutide are emerging as promising pharmacological treatments. This study aimed to evaluate the effects of a 3-month liraglutide treatment on liver steatosis, subclinical markers, and insulin resistance in non-diabetic, obese patients with MASLD. Twenty-eight obese adults (BMI ≥ 30 kg/m2) were treated with daily subcutaneous liraglutide injections for three months. Liver steatosis was assessed using FibroScan® (CAP score) and non-invasive indices (Hepatic Steatosis Index—HSI, and NAFLD Liver Fat Score—NLFS). Insulin resistance was measured with conventional markers (HOMA-IR, QUICKI) and triglyceride-based indices (METS-IR, TyG). Liraglutide significantly reduced liver steatosis (CAP score: 305 to 268 dB/m, p &lt; 0.05) and improved HSI, while NLFS remained unchanged. Despite significant weight loss, traditional insulin resistance markers remained unchanged, while METS-IR and TyG improved. Liraglutide therapy improved liver steatosis and triglyceride-based insulin resistance markers in non-diabetic obese patients with MASLD. These findings support the use of liraglutide, highlighting the value of personalized approaches and alternative insulin resistance assessments in MASLD management.</jats:p>","journal":"International Journal of Molecular Sciences","year":2025,"id":632271,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1638849,"name":"Łukasz Bułdak","orcid":"0000-0002-2017-5516","position":1,"is_corresponding":false},{"id":1638851,"name":"Michał Nicze","orcid":null,"position":2,"is_corresponding":false},{"id":1638853,"name":"Bogusław Okopień","orcid":"0000-0001-7228-2906","position":3,"is_corresponding":false},{"id":1638846,"name":"Aleksandra Bołdys","orcid":"0000-0002-1206-8702","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study","abstract":"<jats:p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of liver cirrhosis, with its global prevalence rising due to obesity, insulin resistance, and type 2 diabetes mellitus. While bariatric surgery remains effective for weight loss, Glucagon-Like Peptide-1 analogs such as liraglutide are emerging as promising pharmacological treatments. This study aimed to evaluate the effects of a 3-month liraglutide treatment on liver steatosis, subclinical markers, and insulin resistance in non-diabetic, obese patients with MASLD. Twenty-eight obese adults (BMI ≥ 30 kg/m2) were treated with daily subcutaneous liraglutide injections for three months. Liver steatosis was assessed using FibroScan® (CAP score) and non-invasive indices (Hepatic Steatosis Index—HSI, and NAFLD Liver Fat Score—NLFS). Insulin resistance was measured with conventional markers (HOMA-IR, QUICKI) and triglyceride-based indices (METS-IR, TyG). Liraglutide significantly reduced liver steatosis (CAP score: 305 to 268 dB/m, p &lt; 0.05) and improved HSI, while NLFS remained unchanged. Despite significant weight loss, traditional insulin resistance markers remained unchanged, while METS-IR and TyG improved. Liraglutide therapy improved liver steatosis and triglyceride-based insulin resistance markers in non-diabetic obese patients with MASLD. These findings support the use of liraglutide, highlighting the value of personalized approaches and alternative insulin resistance assessments in MASLD management.</jats:p>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40565353","pmcid":"PMC12192618","openalex_id":"https://openalex.org/W4411453788","authors":[],"funders":[{"funder_name":"Medical University of Silesia in Katowice","grant_id":"BNW-1-157/N/4/K","title":null}],"total_grants":1,"fwci":6.7006,"citation_percentile":0.97371696,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":6}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1422-0067/26/12/5883/pdf?version=1750331815","host_type":"journal"},{"url":"https://www.mdpi.com/1422-0067/26/12/5883/pdf?version=1750331815","host_type":"publisher"},{"url":"https://www.mdpi.com/1422-0067/26/12/5883/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/ijms26125883","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40565353","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12192618","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12192618","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12192618?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Liver Disease Diagnosis and Treatment","Diet and metabolism studies","Diabetes Treatment and Management"],"mesh_terms":["Liraglutide","Adult","Fatty Liver","Female","Humans","Hypoglycemic Agents","Insulin Resistance","Male","Middle Aged","Obesity","Prospective Studies","Biomarkers","Non-alcoholic Fatty Liver Disease"],"keywords":["Liraglutide","Steatosis","Medicine","Liver steatosis","Diabetes mellitus","Internal medicine","Prospective cohort study","Obesity","Fatty liver","Endocrinology","Gastroenterology","Type 2 diabetes","Glp-1 Analog","Non-invasive Markers","Masld"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T09:23:29.356084Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}